Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Malignant Tumor of LiverRandomized Controlled Trial
Interventions
PROCEDURE

NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration

After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.

PROCEDURE

NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration

After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.

Trial Locations (1)

614000

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
collaborator

Nanjing Chia-Tai Tianqing Pharmaceutical Company

UNKNOWN

lead

West China Hospital

OTHER